אקטמרה 20 מגמל i.v.
roche pharmaceuticals (israel) ltd - tocilizumab - תרכיז להכנת תמיסה לאינפוזיה - tocilizumab 20 mg/ml - tocilizumab - tocilizumab - actemra (tocilizumab) is indicated for reducing signs and symptoms in adult patients with moderately to severely active rheumatoid arthritis who had an inadequate response to one or more dmards (disease modifying antirhematic drugs) or tnf antagonists or in whom dmards cannot be used. actemra can be used alone or in combination with methotrexate or other dmards.actemra® has been shown to reduce progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. actemra® is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older.
יומירה
abbvie biopharmaceuticals ltd, israel - adalimumab - תמיסה להזרקה - adalimumab 100 mg / 1 ml - adalimumab
רינבוק 15 מג
abbvie biopharmaceuticals ltd, israel - upadacitinib as hemihydrate - טבליות בשחרור ממושך - upadacitinib as hemihydrate 15 mg - upadacitinib
רינבוק 15 מג
abbvie biopharmaceuticals ltd, israel - upadacitinib as hemihydrate - טבליות בשחרור ממושך - upadacitinib as hemihydrate 15 mg - upadacitinib
היירימוז
novartis israel ltd - adalimumab - תמיסה להזרקה - adalimumab 50 mg/ml - adalimumab
רמסימה 120 מגמל תת-עורי
padagis israel agencies ltd, israel - infliximab - תמיסה להזרקה - infliximab 120 mg/ml - infliximab
רינבוק 30 מג
abbvie biopharmaceuticals ltd, israel - upadacitinib as hemihydrate - טבליות בשחרור ממושך - upadacitinib as hemihydrate 30 mg - upadacitinib
יופלימה
padagis israel agencies ltd, israel - adalimumab - תמיסה להזרקה - adalimumab 100 mg/ml - adalimumab
רינבוק 45 מג
abbvie biopharmaceuticals ltd, israel - upadacitinib as hemihydrate - טבליות בשחרור ממושך - upadacitinib as hemihydrate 45 mg - upadacitinib
סטלרה 45 מג ויאל
j-c health care ltd - ustekinumab - תמיסה להזרקה - ustekinumab 45 mg / 0.5 ml - ustekinumab - ustekinumab - stelara™ is indicated for the treatment of moderate to severe plaque psoriasis in adult patients (18 years or older) who have failed to,or have contraindication to or who are intolerant to other systemic therapies including ciclosporin,methotrexate and psoralen plus u.v (puva).